Psychopharmacology of autism spectrum disorders: a selective review (Q38034655)

27 August 2017

title

Psychopharmacology of autism spectrum disorders: a selective review (English)

1 reference

27 August 2017

main subject

autism spectrum disorder

0 references

0 references

Sarah Mohiuddin

1 reference

27 August 2017

Mohammad Ghaziuddin

series ordinal

1 reference

27 August 2017

publication date

14 August 2012

1 reference

27 August 2017

1 reference

27 August 2017

1 reference

27 August 2017

1 reference

27 August 2017

page(s)

645-654

1 reference

Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Medication patterns in patients with autism: temporal, regional, and demographic influences

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Divalproex versus placebo for the prevention of irritability associated with fluoxetine treatment in autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Risk factors for self-injurious behaviours among 222 young children with autistic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Autism: towards an integration of clinical, genetic, neuropsychological, and neurobiological perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Imipramine in preschool autistic and schizophrenic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Long-Term Prognosis and the Response of Schizophrenic Children to Drug Therapy : A Controlled Study of Trifluoperazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Depression in persons with autism: implications for research and clinical care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Adverse effects of atypical antipsychotics : differential risk and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Clonidine treatment of hyperactive and impulsive children with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Psychopharmacological treatment of psychotic children: A SURVEY

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Follow-up study of eleven autistic children originally reported in 1943

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

A systematic review of medical treatments for children with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Use of methylphenidate in the treatment of children with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Psychotropic medication use among children with autism spectrum disorders enrolled in a national registry, 2007-2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Clinical efficacy of fluvoxamine and functional polymorphism in a serotonin transporter gene on childhood autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1362361312453776

21 January 2018

Identifiers

DOI

10.1177/1362361312453776

1 reference

27 August 2017

1 reference